INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 410m ago
HOUSE PTR9m ago
SEC 13F9m ago
ROBINHOOD CHAIN9m ago
Public company

CLDXCelldex Therapeutics, Inc.

CIK 0000744218

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 1
Max Insider Score28
Connections10with evidence

CLDX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
JR
Jain RitaDirector
CLDXCelldex Therapeutics, Inc.
Grant or award
A—
26.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Nov 4, 2026
  • ← Lobbied forevidence
    AKIN GUMP STRAUSS HAUER & FELDLDA Q1Y 2026 first quarter · issues not listed · Aug 26, 2026
  • ← Insider ofevidence
    Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS · Jun 29, 2026
  • ← Insider ofevidence
    Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN. · Jun 29, 2026
9
MB
Martin Samuel BatesSVP AND CFO
CLDXCelldex Therapeutics, Inc.
Grant or award
A
—
93.0K sh
Jun 25, 2026
Jun 29, 2026
traded Jun 25, 2026
+4d
SEC FORM 4

Evidence

9
CE
Crowley ElizabethSR. VP & CPDO
CLDXCelldex Therapeutics, Inc.
Grant or award
A—
100.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
LL
Lawver Teri LSVP & Chief Commercial Officer
CLDXCelldex Therapeutics, Inc.
Grant or award
A—
90.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

5
JA
Jimenez Freddy A.SVP & GENERAL COUNSEL
CLDXCelldex Therapeutics, Inc.
Grant or award
A—
93.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
TD
Torres DeniceDirector
CLDXCelldex Therapeutics, Inc.
Grant or award
A—
26.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
HM
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
CLDXCelldex Therapeutics, Inc.
Grant or award
A—
95.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
CS
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
CLDXCelldex Therapeutics, Inc.
Grant or award
A—
95.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

28
JA
Jimenez Freddy A.SVP & GENERAL COUNSEL
CLDXCelldex Therapeutics, Inc.
Open-market sale
SELL$121K
4,166 sh
Dec 4, 2025Dec 8, 2025
traded Dec 4, 2025
+4dSEC FORM 4

Evidence

9
LL
Lawver Teri LSVP & Chief Commercial Officer
CLDXCelldex Therapeutics, Inc.
Grant or award
A—
100.0K sh
Nov 10, 2025Nov 12, 2025
traded Nov 10, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Jain RitaDirector · Jun 29, 2026
  • ← Insider ofevidence
    Crowley ElizabethSR. VP & CPDO · Jun 29, 2026
  • ← Insider ofevidence
    Martin Samuel BatesSVP AND CFO · Jun 29, 2026
  • ← Insider ofevidence
    Torres DeniceDirector · Jun 29, 2026
  • ← Insider ofevidence
    Jimenez Freddy A.SVP & GENERAL COUNSEL · Dec 8, 2025
  • ← Insider ofevidence
    Lawver Teri LSVP & Chief Commercial Officer · Nov 12, 2025

    • Lobbying

    $150K reported · de-duplicated
    2026 Q2 $90K via firms2026 Q1 $60K via firms
    • AKIN GUMP STRAUSS HAUER & FELD$90K2026 Q2 · posted Aug 26, 2026 · Health issues
    • AKIN GUMP STRAUSS HAUER & FELD$60K2026 Q1 · posted Aug 26, 2026 ·

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.